SCHEMBL32663545

SCHEMBL32663545

CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCN5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1

nearest known ligand 0.86

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 16/20 0.86
▸ NSD2 O96028 1/20 0.86
▸ ADORA3 P0DMS8 1/20 0.86
▸ CYP2C9 P11712 1/20 0.86
▸ ADRA2C P18825 1/20 0.86
▸ SLC6A2 P23975 1/20 0.86
▸ BID P55957 1/20 0.86
▸ SLC6A3 Q01959 1/20 0.86
▸ BCL2L1 Q07817 1/20 0.86
▸ MCL1 Q07820 1/20 0.86
▸ ASPH Q12797 1/20 0.86
▸ BCL2L2 Q92843 1/20 0.86
▸ BAD Q92934 1/20 0.86
▸ NSD1 Q96L73 1/20 0.86
▸ NSD3 Q9BZ95 1/20 0.86
▸ HDAC1 Q13547 3/20 0.84
▸ HDAC6 Q9UBN7 3/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1701494 1.00 BCL2 (0.86) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL21542161 0.95 BCL2 (0.83) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL25917595 0.95 BCL2 (0.88) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL29131196 0.94 BCL2 (0.86) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL30802176 0.94 BCL2 (0.82) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL21542163 0.94 BCL2 (0.82) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL19503859 0.93 BCL2 (0.87) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL19419617 0.93 BCL2 (0.92) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL24917621 0.93 BCL2 (0.76) BCL2NSD2ADORA3CYP2C9ADRA2C
SCHEMBL1956773 0.93 BCL2 (0.87) BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4682148-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Ireland Unlimited Company (IE) 2026-01-21 — — EP disclosed
Send feedback